ABT-450 — Competitive Intelligence Brief

ABT-450 (ABT-450) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: protease inhibitor. Area: Infectious Diseases.

phase 2 protease inhibitor HCV protease Infectious Diseases Small molecule

Target snapshot

ABT-450 (ABT-450) — AbbVie (prior sponsor, Abbott). ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT-450 TARGET	ABT-450	AbbVie (prior sponsor, Abbott)	phase 2	protease inhibitor	HCV protease
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Victrelis	BOCEPREVIR	Merck & Co.	marketed	Hepatitis C Virus NS3/4A Protease Inhibitor	Chymase	2011-01-01
Prezista	DARUNAVIR	Janssen Prods	marketed	Protease Inhibitor [EPC]	Multidrug resistance protein 1	2006-01-01
TIPRANAVIR	TIPRANAVIR		marketed	Protease Inhibitor [EPC]		2005-01-01
Reyataz	ATAZANAVIR	Bristol-Myers Squibb	marketed	Protease Inhibitor	UDP-glucuronosyltransferase 1-1	2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
• 2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (protease inhibitor class)

1. Tibotec Pharmaceuticals, Ireland · 3 drugs in this class
2. AbbVie · 1 drug in this class
3. AbbVie (prior sponsor, Abbott) · 1 drug in this class
4. R-Pharm · 1 drug in this class
5. Tanabe Pharma Corporation · 1 drug in this class